Subscribe To
Sesen bio to conduct additional trial for potential resubmission of vicineum in bladder cancer
Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive ...
December 9, 2021, 1:09 pm
Sesen bio to conduct additional trial for potential resubmission of vicineum in bladder cancer
Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive ...
December 9, 2021, 1:09 pm
Sesen bio to conduct additional trial for potential resubmission of vicineum in bladder cancer
Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive ...
December 9, 2021, 1:09 pm